ACRS
Aclaris Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACRS
Aclaris Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases
701 Lee Road, Suite 103, Wayne, PA 19087
--
Aclaris Therapeutics, Inc., was founded in July 2012 in Delaware, USA. The company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune inflammatory diseases.
Company Financials
EPS
ACRS has released its 2025 Q3 earnings. EPS was reported at -0.12, versus the expected -0.14, beating expectations. The chart below visualizes how ACRS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACRS has released its 2025 Q3 earnings report, with revenue of 3.30M, reflecting a YoY change of -24.09%, and net profit of -14.61M, showing a YoY change of -92.64%. The Sankey diagram below clearly presents ACRS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
